US$ 25.55
cjc-1295 plus ipamorelin + – Peptide Foundry What Is CJC 1295 Ipamorelin?
Description
Signal Transduct Target Ther

In addition, several clinical trials in phase I and II of IGF-1R tyrosine kinase inhibitors such as OSI-906 are underway (Pitts et al., 2010)

This compound is supplied as a research-grade preparation intended for controlled laboratory use in analytical, biochemical, and in-vitro research applications

Meets USP disintegration for maximum bioavailability
